Laboratory, optical and precision equipments (excl. glasses)

Tender description

North Bristol NHS Trust is intending to purchase by way of seperate lots either a SNP Microarrays (capable of CNV detection and SNP genotyping) or equipment capable of large scale massively parallel (Next Generation) sequencing and scanning SNP Microarrays (capable of CNV detection and SNP genotyping) as part of the wider Pathology Sciences and the South West Genomic Laboratory Hub strategy and to meet the requirements of the NHSE National Genomic Test Directory for Cancer. Consideration will also be given for platforms that meet the requirements of the NHSE National Genomic Test Directory for Rare Disease and Cancer. The system must be capable of enabling batch flexibility to ensure efficient and responsive running of these urgent clinically urgent services. The South West Genomics Laboratory Hub is intending to purchase equipment capable of scanning SNP Microarrays (capable of CNV detection and SNP genotyping) as part of the wider Pathology Sciences and the South West Genomic Laboratory Hub strategy and to meet the requirements of the NHSE National Genomic Test Directory for Cancer. The equipment is required to streamline current service delivery onto a consolidated pipeline suitable for Cancer investigations, including FFPE testing, as well as facilitating more specialised applications, for example combined methylation and copy number assessment or genome wide gene expression studies. Consideration will also be given for platforms that meet the requirements of the NHSE National Genomic Test Directory for Rare Disease and Cancer. The system must be capable of enabling batch flexibility to ensure efficient and responsive running of these urgent clinically urgent services. The South West Genomics Laboratory Hub (SWGLH) is intending to purchase equipment capable of large scale massively parallel (Next Generation) sequencing and scanning SNP Microarrays (capable of CNV detection and SNP genotyping) as part of the wider Pathology Sciences and the South West Genomic Laboratory Hub strategy and to meet the requirements of the NHSE National Genomic Test Directory for Cancer and Rare Disease. The equipment is required to expand existing next generation sequencing capacity across the SWGLH Cancer and Rare Disease services and to streamline aspects of current and predicted service delivery onto a consolidated microarray pipeline suitable for Cancer and Rare Disease investigations.